Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Zibelman

Showing results (1-10 of 56) with videos related to

Pageof 6
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|May 17, 2019
Full Spectrum: Efficacy and Toxicity of Immunotherapy in Metastatic MelanomaMatthew Zibelman, Anthony Olszanski
Cancers|February 13, 2026
Perioperative Immune-Checkpoint Inhibition in Renal Cell Carcinoma: Lessons Learned and Future DirectionsAdam Adika, Matthew Zibelman
American Journal of Clinical Oncology|March 12, 2016
Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and NeckMatthew Zibelman, Ranee Mehra
Annals of Translational Medicine|October 3, 2019
Pembrolizumab plus ipilimumab or pegylated interferon alfa-2b for patients with melanoma or renal cell carcinoma: take new drugs but keep the old?Matthew Zibelman, Elizabeth R Plimack
Future Oncology (London, England)|July 13, 2016
Systemic therapy for bladder cancer finally comes into a new ageMatthew Zibelman, Elizabeth R Plimack
Immunotherapy|March 23, 2018
Immunotherapy for metastatic urothelial carcinoma: putting the brakes on releasing the brakeMatthew Zibelman, Elizabeth R Plimack
Oncology (Williston Park, N.Y.)|February 19, 2016
Checkpoint Inhibitors and Urothelial Carcinoma: The Translational ParadigmMatthew Zibelman, Elizabeth R Plimack
Journal of the National Comprehensive Cancer Network : JNCCN|June 10, 2017
Integrating Immunotherapy Into the Management of Renal Cell CarcinomaMatthew Zibelman, Elizabeth R Plimack
Journal of Personalized Medicine|November 18, 2020
Biomarker Development for Metastatic Renal Cell Carcinoma: Omics, Antigens, T-cells, and BeyondBenjamin Miron, David Xu, Matthew Zibelman
Future Oncology (London, England)|June 1, 2018
Impact of tumor microenvironment composition on therapeutic responses and clinical outcomes in cancerFern Anari, Chethan Ramamurthy, Matthew Zibelman
Pageof 6

Showing results (1-10 of 56) with videos related to

Sort By:
Pageof 6
Journal of the National Comprehensive Cancer Network : JNCCN|May 17, 2019
Full Spectrum: Efficacy and Toxicity of Immunotherapy in Metastatic MelanomaMatthew Zibelman, Anthony Olszanski
Cancers|February 13, 2026
Perioperative Immune-Checkpoint Inhibition in Renal Cell Carcinoma: Lessons Learned and Future DirectionsAdam Adika, Matthew Zibelman
American Journal of Clinical Oncology|March 12, 2016
Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and NeckMatthew Zibelman, Ranee Mehra
Annals of Translational Medicine|October 3, 2019
Pembrolizumab plus ipilimumab or pegylated interferon alfa-2b for patients with melanoma or renal cell carcinoma: take new drugs but keep the old?Matthew Zibelman, Elizabeth R Plimack
Future Oncology (London, England)|July 13, 2016
Systemic therapy for bladder cancer finally comes into a new ageMatthew Zibelman, Elizabeth R Plimack
Immunotherapy|March 23, 2018
Immunotherapy for metastatic urothelial carcinoma: putting the brakes on releasing the brakeMatthew Zibelman, Elizabeth R Plimack
Oncology (Williston Park, N.Y.)|February 19, 2016
Checkpoint Inhibitors and Urothelial Carcinoma: The Translational ParadigmMatthew Zibelman, Elizabeth R Plimack
Journal of the National Comprehensive Cancer Network : JNCCN|June 10, 2017
Integrating Immunotherapy Into the Management of Renal Cell CarcinomaMatthew Zibelman, Elizabeth R Plimack
Journal of Personalized Medicine|November 18, 2020
Biomarker Development for Metastatic Renal Cell Carcinoma: Omics, Antigens, T-cells, and BeyondBenjamin Miron, David Xu, Matthew Zibelman
Future Oncology (London, England)|June 1, 2018
Impact of tumor microenvironment composition on therapeutic responses and clinical outcomes in cancerFern Anari, Chethan Ramamurthy, Matthew Zibelman
Pageof 6